RAS testing in metastatic colorectal cancer: advances in Europe

Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients with metastatic colorectal cancer. Recent studies have shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Krieken, J Han JM, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Normanno, Nicola, Patterson, Scott D., Jung, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review and Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830882/
https://www.ncbi.nlm.nih.gov/pubmed/26573425
http://dx.doi.org/10.1007/s00428-015-1876-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830882/
https://www.ncbi.nlm.nih.gov/pubmed/26573425
http://dx.doi.org/10.1007/s00428-015-1876-7

Ejemplares similares